Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
FLUDARABINE PHOSPHATE
Pharmachemie BV
L01BB05
FLUDARABINE PHOSPHATE
25 Mg/Ml
Concentrate for Soln for Inj
Product subject to prescription which may not be renewed (A)
Purine analogues
Authorised
2007-06-22
Page 1 of 8 1 PACKAGE LEAFLET: INFORMATION FOR THE USER FLUDARABINE PHOSPHATE 25 MG/ML CONCENTRATE FOR SOLUTION FOR INJECTION OR INFUSION fludarabine phosphate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Fludarabine Phosphate 25 mg/ml is and what it is used for 2. What you need to know before you use Fludarabine Phosphate 25 mg/ml 3. How to use Fludarabine Phosphate 25 mg/ml 4. Possible side effects 5. How to store Fludarabine Phosphate 25 mg/ml 6. Contents of the pack and other information 1. WHAT FLUDARABINE PHOSPHATE 25 MG/ML IS AND WHAT IT IS USED FOR Fludarabine Phosphate 25 mg/ml is a cytotoxic (anti-cancer medicine): medicines that inhibit the growth of cancer cells. Fludarabine Phosphate 25 mg/ml is used to treat chronic B-cell lymphocytic leukaemia (B-CLL), in patients with sufficient healthy blood cells production. First treatment for chronic lymphocytic leukaemia with fludarabine phosphate should only be started in patients with advanced disease having disease related symptoms or evidence of disease progression. CLL is a cancer of the white blood cells (called lymphocytes). If you are diagnosed with CLL, too many lymphocytes are produced. They either don't work properly or are too young (immature) to carry out the normal disease fighting functions of white blood cells. If there are too many of these abnormal cells they push aside (displace) healthy blood Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fludarabine Phosphate 25 mg/ml concentrate for solution for injection or infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of concentrate contains 25 mg fludarabine phosphate. Each vial of 2 ml contains 50 mg fludarabine phosphate. Excipient with known effect: Sodium, less then 1 mmol (23 mg) per vial. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Concentrate for solution for injection or infusion. Fludarabine phosphate 25 mg/ml is a clear, colourless or slightly brownish-yellow solution, essentially free from particles. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of B-cell chronic lymphocytic leukaemia (CLL) in patients with sufficient bone marrow reserves. First line treatment with fludarabine should only be initiated in patients with advanced disease, Rai stages III/IV (Binet stage C), or Rai stages I/II (Binet stage A/B) where the patient has disease related symptoms or evidence of progressive disease. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adults_ The recommended dose is 25 mg fludarabine phosphate/m² body surface given daily for 5 consecutive days every 28 days by the intravenous route. The required dose (calculated on the basis of the patient's body surface) is drawn up into a syringe. For intravenous bolus injection this dose is further diluted into 10 ml of 0.9 % sodium chloride. Alternatively, for infusion, the required dose may be diluted in 100 ml 0.9 % sodium chloride and infused over approximately 30 minutes (see also section 6.6). The optimal duration of treatment has not been clearly established. The duration of treatment depends on the treatment success and the tolerability of the drug. It is recommended that fludarabine be ad Read the complete document